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Women with pathologic levels of antiphospholipid antibodies (aPL) are at high risk for 
recurrent pregnancy loss and preeclampsia. Despite treatment with low molecular weight 
heparin (LMWH), either alone or with low dose aspirin (ASA), the incidence of late-term 
complications remains high for these patients. aPL recognizing β 2 glycoprotein I (β2GPI) 
are particularly harmful during pregnancy as they target the placenta causing insufficient 
spiral artery transformation and inflammation, giving rise to obstetric APS. There have 
been extensive studies into the mechanisms by which aPL affect the placental trophoblast 
which constitutively synthesizes and expresses β2GPI. However, aPL specific for β2GPI 
can also bind to maternal uterine endothelial cells, but much less is known about the 
impact aPL have on the maternal side of the maternal-fetal interface. This study sought to 
characterize the effects of anti-β2GPI aPL on human endometrial endothelial cells 
(HEECs); the role of toll-like receptor-4 (TLR4) in the mechanism of aPL-HEEC 
interactions; and the influence of LMWH and ASA on aPL-mediated HEEC responses 
using in vitro culture systems. aPL, but not control IgG, significantly increased HEEC 
secretion of pro-angiogenic vascular endothelial growth factor (VEGF) and placental 
growth factor (PlGF); increased anti-angiogenic soluble fms-like tyrosine kinase 
receptor-1 (sFlt-1); inhibited basal secretion of the chemokines monocyte 
chemoattractant protein-1 (MCP-1), granulocyte colony-stimulating factor (G-CSF) and 
growth related oncogene- α (GRO-α); and impaired angiogenesis. The aPL-triggered 
inhibition of HEEC MCP-1 was mediated by activation of TLR4. LMWH and ASA, 
alone and in combination, exacerbated the aPL-induced changes in the HEEC angiogenic 
factor and chemokine profile. There was no reversal of the aPL-inhibition of HEEC 
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angiogenesis by either single or combination therapy. In conclusion, HEECs produce 
chemokines necessary for normal trophoblast invasion, immune cell recruitment, and 
spiral artery remodeling. By aPL inhibiting HEEC chemokine secretion and promoting 
sFlt-1 release, the uterine endothelium may contribute to impaired placentation and 
vascular transformation in obstetric APS. Combination LMWH and ASA may further 
contribute to this endothelium dysfunction in women with obstetric APS. 
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Diagnosis of APS 
Antiphospholipid syndrome (APS) is an acquired autoimmune disease in which 
patients have circulating autoantibodies called antiphospholipid antibodies that aberrantly 
recognize certain phospholipid-binding proteins leading to a hypercoaguable state and 
increased risk of recurrent venous and arterial thrombosis. These patients have increased 
risk of stroke and myocardial infarction, among other complications and disease 
manifestations. In women, APS causes increased risk of recurrent fetal loss in addition to 
complications such as hypertension and preeclampsia, preterm labor, premature rupture 
of membranes, and intrauterine growth restriction [1, 2].   
The Sapporo Classification Criteria Guidelines for diagnosis of this disease 
include both clinical and laboratory criteria. Criteria for clinical diagnosis rely on patient 
history while laboratory criteria relies on the presence of certain antibodies. The current 
clinical criteria include: arterial, venous, or small vessel thrombosis, in any organ or 
tissue; and pregnancy morbidity consisting of: 1) one or more unexplained deaths of a 
morphologically normal fetus at or beyond the 10th week of gestation; or 2) one or more 
premature births of morphologically normal neonate at or before the 34th week of 
gestation because of severe preeclampsia, eclampsia or severe placental insufficiency; or 
3) three or more unexplained consecutive spontaneous abortions before the 10th week of 
gestation. The updated laboratory criteria include: medium to high serum titers (greater 
than 40 GPL/MPL or > 99th percentile) of IgG or IgM isotype of anticardiolipin on two 
or more occasions, at least 12 weeks apart measured by standardized ELISA; lupus 
anticoagulant present in plasma on two or more occasions at least 12 weeks apart 
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detected by the guidelines of the International Society of Thrombosis and Haemostasis; 
and anti-beta 2 glycoprotein-I (anti-β2GPI) antibody of IgG or IgM isotype in serum or 
plasma (>99th percentile), also measured at 12 week intervals [1]. 
Given the fact that diagnosis of this disease in women oftentimes relies on 
repeated pregnancy loss, it may require years of symptoms and/or several episodes of 
high-risk gestation before patients receive proper treatment. During pregnancy, women 
with APS are at further increased risk of late-term complications in addition to the 
systemic cardiovascular risks of the disease. Furthermore, women with anti-β2GPI 
antibodies are at highest risk of fetal loss and late-term complications because the 
placental trophoblast synthesizes and expresses β2GPI, making this organ a specific target 
for aPL [3-6]. 
 
Antiphospholipid antibodies in APS 
There are several antibodies that are pathogenic in APS, but, as previously stated, the 
most deleterious in pregnancy are anti-β2GPI aPL. Anti-β2GPI antibodies are a 
heterogeneous group of polyclonal antibodies, which bind to different epitopes of β2GPI, 
a glycosylated, anionic phospholipid-binding glycoprotein that belongs to the 
complement control protein (CCP) superfamily. This protein’s function is still a subject 
of study, but its structure is known. β2GPI has five CCP domains. The first four domains 
have the regular, conserved sequences, but the fifth domain is different. These additional 
amino acids in domain V are responsible for a unique feature of this CCP domain, 
because they constitute a large positively charged patch that determines the affinity for 
anionic phospholipids [7]. Domain V is thought to interact with various cell surface 
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receptors such as apoER2, Toll-like receptors (TLRs), and other negatively charged 
molecules such as heparin, DNA, low density oxidized lipoproteins and annexin II [8]. In 
the serum, β2GPI is circular with domain V binding to the cell surface causing a 
conformational change, thus exposing the other CCP domains. β2GPI localizes to the 
syncytiotrophoblast cells that are in direct contact with maternal blood [3, 9] as well as 
the invasive cytotrophoblast and extravillous trophoblast cells. In addition, serum β2GPI 
can also localizes to human endometrial endothelial cells, which the invasive trophoblasts 
invade and replace during normal spiral artery transformation [10]. Thus, both the 
trophoblast and endometrial endothelial cells are a target for anti-β2GPI aPL. Studies 
have shown that different epitopes on β2GPI are recognized by different aPL, with only 
some of these populations having pathological significance in aPL [11-13], though there 
is debate between which domains and epitopes are more pathogenic than others. 
Depending on the epitopes to which they bind, aPL can have varying functional and 
pathogenic effects on the cells they attack [14]. aPL recognizing β2GPI do not only bind 
trophoblasts, but can also affect the maternal side of the uteroplacental interface by 
binding directly to the endometrial endothelial cells [15-17]. Animal models have 
supported a role for anti-β2GPI aPL in the pathogenesis of pregnancy failure and 
complications. Immunization of animals with β2GPI or passive transfer of aPL to mice 
lead to pregnancy complications often seen in APS, namely fetal demise and IUGR, as 
well as reduced litter size and fetal resorption equivalent to implantation failure and 






To form a normal placenta, a fertilized egg, a zygote, undergoes a process of cleavages 
into a collection of cells called a blastula and differentiates into what is called a 
blastocyst. The blastocyst contains a blastocoel, or fluid-filled blastocyst cavity, which 
contains an inner mass of cells called the embryoblast, that will form the fetus. The 
blastocyst also contains an outer layer of cells called the trophoectoderm, which forms 
the placenta. The blastocyst interacts with and implants into the maternal decidua. After 
contact and adhesion of the blastocyst to the uterine epithelium, trophoblast cells 
differentiate into a fusion lineage, the syncytiotrophoblast, and an invasive lineage, the 
cytotrophoblast. The invasive lineage of trophoblasts penetrate deep into the maternal 
decidua, differentiating into extravillous trophoblasts, through to the smooth muscle layer 
called the myometrium. This lineage of trophoblasts is also responsible for invading the 
uterine spiral arteries where they differentiate into endovascular trophoblast. Eventually 
they interact with and replace the endometrial endothelial cells in the spiral arteries order 
to form large caliber vessels for a well-rooted placenta with a large-volume blood supply 
in a process called vascular transformation [20].  
In order for this placentation to occur, endothelial and decidual cells must 
adequately promote trophoblast invasion, immune cell recruitment, and spiral artery 
remodeling via the secretion and excretion of factors, cytokines, and chemokines, to 
establish the adequate placentation and vascular development needed for a healthy 
pregnancy. Normal placentation relies on successful vascular transformation and 
angiogenesis which leads to the expansion in size and number of vasculature at the 
maternal-fetal interface and of the placenta and decidua. Extravillous trophoblasts invade 
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the spiral arteries disrupting the smooth muscle cells, and interacting with and ultimately 
replacing the endothelial cells. This transforms them into high flow, low resistance 
vessels necessary to support the fetus through the term of pregnancy. If this process is 
aberrant and there is a failure of trophoblast contact, adhesion, invasion, and vascular 
transformation, pregnancy complications associated with insufficient placentation may 
result. In obstetric APS, preeclampsia is the most common complication associated with 
inadequate placentation. There are many proposed mechanisms for this observed 
pathology.  
 
Preeclampsia and abnormal placentation in APS 
Impaired angiogenesis and vascular development/remodeling. 
Gestational hypertension and preeclampsia are likely due to insufficient placentation and 
poor spiral artery transformation. Since APS is a syndrome which affects the caliber of 
placentation, obstetric APS shares many features of preeclampsia. Clinical signs of 
inadequate placentation are placental hypoperfusion and ischemia which cause increased 
resistance in placental vessels and vascular endothelial stress. Clinical signs of 
preeclampsia in the mother are characterized by the onset of high blood pressure and 
often a significant amount of protein in the urine in addition to end-organ damage as a 
result of the hypertension after 20 weeks of pregnancy. In severe cases, preeclampsia can 
lead to eclampsia, which is characterized by maternal seizures and can progress to more 
severe liver, kidney, and retinal damage, systemic edema, and thrombocytopenia [21]. 
There are many potential causes of preeclampsia, but it is clear that some sort of placental 
injury or insults create the hypertensive phenotype of the disease and immediate delivery 
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of the fetus and placenta is the therapy of choice. Preeclampsia presents risks to the 
mother and fetus as immediate delivery due to potential end-organ damage of a 
potentially premature fetus represents a significant deviation from normal uncomplicated 
pregnancy. Premature births are at risk of cerebral hemorrhage and inadequate lung 
development. Women with preeclampsia are also at risk of further cardiovascular 
complications after delivery [22]. 
Preeclampsia is hypothesized to be as result of early aberrations in placental 
vascular remodeling, though it often presents as a late-term complication. Altered 
vascular reactivity, impaired trophoblast invasion, increased oxidative stress, 
deregulation of vasoactive substances, immune response and deregulation of angiogenic 
factor secretion have all been attributed to causing preeclampsia [21, 23, 24]. Similarly in 
obstetric APS, inadequate placentation and deregulation of angiogenic factor secretion 
has been shown to cause preeclampsia [25-27]. Furthermore, mouse models have 
suggested that two placental anti-angiogenic proteins, circulating sFlt1 and soluble 
endoglin (sEndoglin), play a causal role in the pathogenesis of preeclampsia [28, 29]. 
sEndoglin is a truncated, soluble form of Eng, which antagonizes transforming growth 
factor-β (TGF-β). TGF-β has many functions, but it is also a potent angiogenic factor and 
upregulates VEGF, in early gestational trophoblasts [29]. sFlt1 is a soluble, truncated 
variant of the VEGF receptor, Flt1. sFlt1 acts as a potent antagonist to VEGF and PlGF. 
VEGF and PlGF are both pro-angiogenic factors [30]. Placental growth factor is pro-
angiogenic as it enhances the activity of VEGF by competitively binding to the VEGF 
receptor-1, allowing VEGF to bind then to VEGF receptor-2 which has stronger tyrosine 
kinase activity [31]. Studies have also shown that heterodimers of VEGF and PlGF act as 
12	
	
pro-angiogenic factors [32, 33]. Both VEGF and PlGF are made by the placenta and 
circulate in high concentration during pregnancy. There is an observed downregulation of 
circulating vascular endothelial growth factor, VEGF, and placental growth factor, PlGF 
and a marked increase in sFlt-1 and sEndoglin [21] in preeclampsia. Furthermore, a study 
by Levine et al. showed that rising circulating serum levels of sEndoglin and ratios of 
sFlt1:PlGF predict the onset of preeclampsia in pregnant patients [34]. In patients with 
APS, Cuadrado et al. demonstrated that VEGF may stimulate monocyte tissue factor 
expression through its receptor, Flt-1, contributing to the proinflammatory-prothrombotic 
phenotype of obstetric APS patients [25]. 
 
Reduced cytotrophoblast invasiveness 
sFlt1 has also been shown to decrease cytotrophoblast invasiveness in vitro [35]. 
Reduced cytotrophoblast invasion is a shared characteristic between preeclampsia and 
obstetric APS. Di Simone et al. found that direct action of polyclonal patient derived aPL 
on cytotrophoblasts has been associated with reduced placental human chorionic 
gonadotropin (hCG) and placental placental lactogen (hPL) secretion and a complete 
block of trophoblast invasiveness and adhesion [36]. Similar findings were replicated by 
Katsuragawa et al. which found that monoclonal aPLs decrease trophoblast hCG and hPL 
secretion and block trophoblast invasiveness [37].  
Trophoblast adhesion is also negatively affected by the trophoblast. Zhou et al. 
found that in normal placental development the cytotrophoblasts assume an endothelial 
phenotype in a process called vascular mimicry, or pseudovasculogenesis, by 
downregulating the expression of adhesion molecules characteristic of their epithelial cell 
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origin and adopting an endothelial cell surface adhesion phenotype [38]. In preeclampsia, 
cytotrophoblasts do not undergo switching of cell-surface molecules and are unable to 
invade the myometrial spiral arteries [39]. In obstetric APS, Di Simone et al. were able to 
demonstrate that patient derived aPLs are able to change the expression of trophoblast 
adhesion molecules [40]. Furthermore, they were able to show that aPL are able to 
mediate trophoblast gonadotropin secretion and reduced invasion through direct binding 
to adhered β2GPI. Our group also found two domain V anti-β2GPI Abs (ID2 and IIC5) 
inhibit first trimester trophoblast cell migration by downregulating IL-6 production. This 
inhibition leads to decreased signal transducer and activator of transcription 3 (STAT3) 
activity. By using a blocking anti-IL-6R antibody, IL-6 was shown to be partly 
responsible for trophoblast cells’ spontaneous migratory capacity [41].  
 
Dysfunctional immune cell recruitment and inflammation 
Although systemic APS is known and studied as a pro-thrombotic disorder, 
obstetric APS has been increasingly been shown to be a disorder of inflammation. 
Previously, the prevailing hypothesis was that, similar to the pathophysiology of stroke, 
myocardial infarction, and venous thromboembolism in patients with systemic APS, the 
pathophysiology of recurrent pregnancy loss in pregnant patient with APS was due to 
clotting at the maternal-fetal interface [42-44]. This hypothesis was supported by the 
apparent success of the anti-thrombotic heparin combined with anti-platelet aspirin at 
increasing live birth weight. However, histological studies of placentas with APS confirm 
more prevalent inflammation rather than intraplacental thrombosis at the maternal-fetal 
interface including inflammatory cytokine expression, immune cell infiltration and 
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complement deposition [6, 45, 46]. Sebire et al. found that defective trophoblast invasion 
and spiral artery transformation was more often seen in aPL positive placentas, while 
there was no significant increase in thrombotic events between aPL positive and aPL 
negative placentas [47]. Similarly, Stone et al. showed that the placentas of these patients 
become infiltrated with inflammatory immune cells such as macrophages [46]. Salmon 
and Girardi showed using in vivo mouse models that aPL activate both classical and 
alternative complement pathways. Complement activation propagates injury to the fetus 
by recruiting inflammatory neutrophils, inducing their expression of tissue factor (TF), 
and overwhelming the trophoblast’s normal inhibitory mechanisms [48]. This also 
potentiates inflammation in the decidua and leading to miscarriages [49]. Thus, while 
immune cells are necessary for promoting trophoblast recruitment, spiral artery 
remodeling, angiogenesis, and thus, successful implantation [50, 51], unregulated 
inflammation can cause defective placentation.  
 
Mechanisms of placental inflammation in obstetric APS 
It is hypothesized that anti-B2GPI aPL bind to membrane-bound β2GPI 
complexed with anionic transmembrane receptors and intracellular ligands on the surface 
of cells such as monocytes, trophoblasts, endothelial cells, and others. In this way, aPL 
are able to effect mechanisms of innate immunity, trophoblast proliferation, and cellular 
regulation of homeostasis [52]. However, the mechanisms of thrombotic and non-
thrombotic aPL-mediated cellular changes are unclear, especially in the case of obstetric 
APS which is seen as a subset of APS and may have distinct pathogenic mechanisms. 
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Alone, one of β2GPI’s alleged functions is as a component of innate immunity. 
Agar et al. showed that binding of β2GPI to LPS caused a conformational change in 
β2GPI that led to binding of the β2GPI-LPS complex to monocytes and ultimately 
clearance of this complex [53]. β2GPI, once it is bound to aPL, has also been shown to 
bind and augment its interaction with transmembrane and intracellular ligands similarly 
to microbial and murine studies have shown that bacteria partially homologous with 
β2GPI structure are able to induce the generation of pathogenic anti-β2GPI antibodies 
along with some APS manifestations [54, 55]. Anti- β2GPI antibodies have been shown 
to interact with many innate immune receptors such as toll-like receptors 2 and 4, most 
commonly, which recognize and bind bacterial LPS, in addition to annexin A2, an 
extracellular receptor for plasminogen and tissue type plasminogen activator, and 
apolipoprotein E receptor-2 (apoER2), involved in endocytosis of ligands and signal 
transduction [7, 56]. Thus, microbial mimicry may be the mechanism by which aPL are 
able to alter cellular response, not by inducing thrombosis through the complement 
cascade or interfering with thrombin and antithrombin III, as has previously been 
hypothesized [57].  
Toll-like receptors have increasingly been associated with increased inflammatory 
cytokine release in systemic APS and more recently in obstetric APS [58]. In systemic 
APS, TLRs have been found to facilitate activation of monocytes and endothelial cells by 
aPL in vitro and in vivo [59, 60].  And a recent study by Laplante et al. showed that aPL-
mediated effects on the arterial model of thrombosis require TLR4 activation [61]. Since 
TLR4 has been established as a necessary receptor in LPS signaling receptor in mice 
studies [62] and has been found to activate endothelial cells in APS [55], homology 
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between LPS and other microbes is seen as the mechanism by which aPL induce an 
inflammatory immune response. This theory was further supported in a study by Sorice et 
al., where it was demonstrated that in monocytes, anti-β2GPI binding Abs causes β2GPI 
and TLR4 to co-localize in lipid rafts and induce interleukin-1 receptor associated kinase 
(IRAK) phosphorylation and nuclear factor-κB (NF-κB) translocation and a subsequent 
release of tumor necrosis factor-α (TNF-α) and TF [63]. TNF-α is a central regulator of 
inflammation and tissue factor is a pro-coagulant. Tissue factor has also been implicated 
in aPL mouse studies where TF blockade prevented aPL antibody–induced inflammation 
and pregnancy loss. TF expression in neutrophils contributes to respiratory burst and 
subsequent trophoblast injury and pregnancy loss induced by aPL antibodies [64]. 
In the trophoblast, our group has shown that aPL induces a pro-inflammatory and 
anti-angiogenic response in first trimester trophoblast via the TLR4/MyD88 pathway 
[65]. Through TLR4 activation, anti-β2GPI antibodies trigger increased trophoblast 
secretion of IL-8, MCP-1, GRO-α, and IL-1β. IL-8 is a potent neutrophil chemoattractant 
cytokine produced by several cells. In vivo, intracutaneous application of IL-8 induces 
local exudation and a massive, long-lasting accumulation of neutrophils [66]. IL-1β is a 
potent pro-inflammatory cytokine important in mediating host immune responses towards 
infection [67]. Not only has IL-1β upregulation been associated with autoimmune disease 
[68], but has also been associated with pre-eclampsia and pre-term birth [69, 70]. MCP-1 
is a chemoattractant for human monocytes (which mature into macrophages) and may 
also activate cellular functions related to host defense [50, 71]. GRO-α is expressed on 
macrophages, neutrophils, and epithelial cells and has chemotactic properties for 
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neutrophils and is important in promoting successful spiral artery transformation and 
implantation [51].  
 
Effect of aPL on endothelial cells in obstetric APS 
The effect of aPL on the trophoblast has been well studied, however, much about 
the action of aPL on HEECs, the cells which trophoblasts bind to and replace during 
spiral artery transformation, is still unclear. Most aPL-endothelial interactions in 
pregnancy and placentas have been studied using fetus-derived human endothelial cells 
from umbilical veins (HUVECs) as a model for systemic vascular events in APS. Similar 
to findings in the trophoblast [65], aPL recognizing β2GPI are able to activate the 
TLR4/MyD88 signaling pathway in HUVECs [72, 73] and induce an inflammatory 
cytokine/chemokine response [74]. Another study by Raschi et al. also using HUVECs 
showed that both human anti-β2GPI IgM monoclonal antibodies and polyclonal affinity-
purified anti-β2GPI IgG antibodies induce a pro-inflammatory phenotype in endothelial 
cells, most likely via the involvement of TLRs and activation of the MyD88 pathway 
[55]. Di Simone et al. have investigated the influence of aPL on human endometrial 
endothelial cells and confirmed a direct effect of aPL on maternal cells. A 2010 report 
found that human polyclonal aPL significantly decreased the number and length of 
tubules formed by HEECs and reduced newly formed vessels in a murine model. aPL 
also significantly reduces VEGF and matrix metalloproteinase (MMP) production and 
suppressed ΝFκΒ DNA binding activity[16]. In a 2012 study by the same group, low-
molecular weight heparin mitigated the aPL inhibited effects on ΝFκΒ and STAT-3 
activity, VEGF secretion and MMP activity in HEECs [15]. Finally, Di Simone et al. 
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found that a synthetic peptide (that shares an amino acid sequence with domain V of 
β2GPI) competes with aPL binding to HEECs to restore aPL-mediated effects on 
angiogenesis [17]. These studies indicate that aPL have a specific effect in HEECs and 
further investigation is needed to define the spectrum of ways angiogenesis and 
endometrial activity are altered by different aPL.  
 
Preeclampsia, APS, and the use of Therapeutic Low molecular Weight Heparin and 
Aspirin 
In the absence of aPL, heparin, both LMWH and unfractionated (UFH), and low dose 
ASA, have been proposed as potential prophylaxis for preeclampsia and other 
hypertensive disorders like HELLP syndrome in addition to being used to prevent 
unexplained fetal loss [75]. Although LMWH (and UFH) and low dose ASA have long 
been prescribed empirically, their effectiveness has only been demonstrated in cases of 
obstetric APS [76, 77]. However, LMWH and low dose ASA have also been suggested in 
second-trimester pregnancy loss [78] and in pregnancies deemed to be at high risk for 
poor perinatal outcome [79, 80].  
Pregnant women with APS are routinely treated with LMWH, either alone or in 
combination with acetyl-salicylic acid (aspirin, ASA), as soon as possible in pregnancy 
and 6 weeks post-partum, with practice varying amongst physicians and with regard to 
patient disease severity and history [81]. In women with aPL, without a history of 
previous clot, or pregnancy loss, low dose ASA alone is deemed sufficient. In women 
with a history of previous thromboembolism, therapeutic doses of unfractionated heparin 
or LMWH are recommended. In women with medium titers of anti-cardiolipin 
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antibodies, anti-β2GPI antibodies or lupus anticoagulant, and who have a history of 2 or 
more early pregnancy losses, fetal deaths or >1 preterm births, low dose ASA along with 
prophylactic doses of UFH or LMWH is the standard of care [82]. However, studies 
regarding each medication’s effectiveness for preventing RPL in the setting of aPL are 
controversial [83, 84]. Heparin has been shown in previous studies to increase incidence 
of live birth weight and reduced rates of fetal loss. A study by Girardi et al. showed that 
heparin prevents fetal loss by inhibiting complement and not through its anticoagulant 
effects [85]. On the other hand, there is evidence that heparin increases the release of 
sFlt-1 and impairs VEGF signaling in placental villi, thereby potentially damaging and 
inhibiting placentation [86]. However, LMWH treatment also resulted in increased 
release of PlGF, whereas sEndoglin release remained unaltered and VEGF was 
undetected. Similarly, a study in 11 preeclamptic women in the third trimester showed 
that administration of LMWH resulted in a 26% mean increase in serum sFlt1 though this 
antiangiogenic effect was partially counterbalanced by a smaller increase in PlGF levels, 
resulting in a less pronounced difference in the ratio between the two concentrations [87]. 
Additionally, heparin does not reverse aPL-mediated changes in trophoblast angiogenic 
factor secretion but instead promotes sFlt-1 release [88]. However, LMWH can dampen 
aPL-induced trophoblast inflammation and complement activation, as shown by Girardi 
et al. in a murine model of APS-mediated pregnancy losses [85]. It must be noted that 
both UFH and LMWH are prescribed and studied, but LMWH has improved 
pharmacokinetics and bioavailability and is less likely to cause heparin-induced 
thrombocytopenia. It is also demonstrably more successful in some studies than 
unfractionated heparin [81], though the difference in pregnancy outcome between UFH 
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and LMWH in APS is also controversial [89]. UFH has also been shown to reduce 
trophoblast invasion in extravillous trophoblasts [90]. Aspirin is used as an adjunct 
medication, but has since been shown to have no significant beneficial effect and may no 
longer be indicated [91]. However, combination low molecular weight heparin and 
aspirin are still administered for obstetric APS and recent studies contend that early 
administration of aspirin in the first trimester is more beneficial than 2nd or 3rd trimester 
administration due to potential benefit in early stages of implantation [63] and beneficial 
effects of LMWH may be through mechanisms distinct of its anticoagulant properties.   
 
Summary  
The impact aPL have on trophoblast function and the mechanisms involved has 
been well studied. Much about the action of aPL on these human endometrial endothelial 
cells (HEECs) is still unclear. Most aPL-endothelial interactions in pregnancy and 
placentas have been studied using fetus-derived HUVECs as a model for systemic 
vascular events in APS. However, to better understand the placental endothelium and the 
nature of the maternal decidua’s interaction with aPL, an additional set of fetally-derived 
cells are not as appropriate to detect key differences and, perhaps, similarities between 
aPL-trophoblast and aPL-endometrium interactions. The objective of this study was to 
elucidate the influence that domain I and V anti-β2GPI aPL have on the maternal uterine 
vasculature using HEECs, and to investigate the role of TLR4. This study also sought to 
evaluate the current therapeutic strategy of LMWH and ASA in counteracting any 





In previous studies, aPL recognizing domain V of β2GPI have been shown to induce 
elevated levels of pro-inflammatory cytokines and chemokines [65]; inhibit spontaneous 
trophoblast migration[41]; and modulate trophoblast angiogenic factor secretion [47]. 
The inflammatory response of trophoblasts to aPL has been confirmed to be mediated by 
innate immune receptor TLR4. Similarly, researchers have studied the effect of aPL on 
systemic APS using HUVECs. This research also found that TLR4 may be influencing 
HUVEC response to aPL. Finally, there is conflicting evidence as to whether domain I or 
domain V anti-β2GPI antibodies are more deleterious in APS pregnancies [73, 92]. Thus, 
my hypothesis is that aPL recognizing domain V, but not domain I induce a pro-
inflammatory and anti-angiogenic profile in HEECs, disrupting their tube formation, 
via activation of TLR4. Furthermore, I hypothesize that LMWH and ASA do not 
attenuate aPL effects on HEECs. 
 
Specific Aims 
1. To characterize the effect of aPL recognizing domain I or domain V of β2GPI 
on HEEC cytokine, chemokine, and angiogenic factor secretion and tube 
formation.  
2. To determine the role of TLR4 in HEEC responses to aPL.  






Materials and Methods 
Reagents 
Sterile low molecular weight heparin (LMWH) (enoxaparin sodium injection; 
100mg/ml), was purchased from Aventis Pharmaceuticals, Inc. (Bridgewater, NJ). 
Acetyl-salicylic acid (ASA) was obtained from Sigma-Aldrich (St. Louis, MO), 
reconstituted in ethanol, and filter-sterilized prior to use. Ethanol alone was included as a 
vehicle control for ASA. The TLR4 antagonist, LPS-RS (Lipopolysaccharide isolated 
from Rhodobacter sphaeroides), was purchased from Invivogen (San Diego, CA). 
 
Human endothelial cells 
The human endometrial endothelial cells (HEECs) used in this study were originally 
isolated from the microvascular of cycling endometrium of multiple women, and all 
stages of cycles were pooled. The primary cells were characterized to express a range of 
adhesion molecules and endothelial markers, and to form endothelial tubes when seeded 
in Matrigel. Subsequently these cells were telomerase immortalized and have been 
characterized to express the same markers and function as the primary cells [93-97].  
 
Human umbilical vein endothelial cells 
Primary human umbilical vein endothelial cells (HUVECs) were obtained from Yale 
University's tissue culture core laboratory, courtesy of Dr. Seth Guller [98]. Cell culture 
was performed as previously described [93, 96] and both cell types were cultured in 
Endothelial Basal Medium-2 (EBM-2) supplemented with 2% fetal bovine serum (FBS) 




This study used two mouse IgG1 anti-human β2GPI monoclonal antibodies (mAbs), ID2 
and IIC5. Like patient-derived polyclonal aPL, both IIC5 and ID2 bind β2GPI in a similar 
manner to human aPL when they are immobilized on negatively charged surfaces such as 
phospholipids, cardiolipin, phosphatidyl serine or irradiated polystyrene [99]. The 
binding of both ID2 and IIC5 to β2GPI is inhibited by patient-derived aPL, and both 
antibodies have been shown to alter trophoblast function similarly to patient-derived 
polyclonal aPL-IgG [100] and polyclonal IgG aPL recognizing β2GPI [65, 88] upon 
binding to first trimester extravillous trophoblast cells, whereas a mouse IgG1 isotype 
control has no effect [65, 88]. IIC5 and ID2 react specifically with an epitope within 
domain V of β2GPI, which may be more important than domain I binding aPL for 
pregnancy morbidity in APS patients [101]. IIC5 also has pronounced lupus 
anticoagulant activity and thus represents a triple positive aPL [102]. This study also used 
one anti-human β2GPI Ab (P1-117) that reacts specifically with an epitope within domain 
I of β2GPI [103, 104]. Mouse IgG1 clone 107.3 (BD Biosciences) was used as an isotype 
control.  
 
Angiogenic factor and chemokine studies 
HEECs (5x105) or HUVECs (5x105) were plated in 60mm tissue culture plates pre-coated 
with 2% gelatin in EBM-2 media supplemented with 2% FBS. The next day the media 
was replaced and the cells treated. HEECs or HUVECs were treated for 72hrs with either 
no treatment (NT), aPL (60µg/ml) or control IgG (60µg/ml) to establish the baseline 
effect of aPL. The aPL dose was determined by preliminary dose response experiments 
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(data not shown) and are similar to other studies [17]. To study the role of TLR4, HEECs 
were treated for 72hrs with NT or aPL in the presence of either media or LPS-RS 
(10µg/mL). To study the effect of current therapeutics on HEEC responses to aPL, cells 
were treated for 72hrs with NT, LMWH (10µg/ml), ASA (10µg/ml) or both LMWH and 
ASA (each at 10µg/ml) in the presence of either media or aPL (60µg/ml). The 
concentrations of ASA and LMWH used in this study were based on a previous study, 
and equivalent to low dose medications used in the clinical setting [105]. After treatment, 
cell-free supernatants were collected and stored at -80°C. Supernatants were then 
measured by ELISA and/or multiplex analysis. The pro-angiogenic factors: vascular 
endothelial growth factor (VEGF) and placental growth factor (PlGF); and the anti-
angiogenic factors: soluble FMS-like tyrosine kinase-1 (sFlt-1) and soluble endoglin 
(sEndoglin) were measured by ELISA (R&D Systems; Minneapolis, MN). The 
chemokines, monocyte chemoattractant protein 1 (MCP-1/CCL2) and granulocyte 
colony-stimulating factor (G-CSF/CSF3) were also measured by ELISA (R&D Systems). 
Multiplex analysis (Bio-Rad, Hercules, CA, USA) was performed for the following 
analytes as previously described [106]: interleukin (IL)-1β; IL-6; IL-8 (CXCL8); IL-10; 
IL-12 (p70); IL-17; growth-regulated oncogene-alpha (GRO-α/CXCL1); granulocyte 
macrophage-colony stimulating factor (GM-CSF/CSF2); interferon gamma (IFNγ); IFN γ 
inducible protein 10 (IP-10/CXCL10); macrophage inflammatory protein 1 alpha (MIP-
1α/CCL3); MIP-1β (CCL4); Regulated on Activation, Normal T Cell Expressed and 
Secreted (RANTES/CCL5) and tumor necrosis factor alpha (TNFα). ELISA was used for 
subsequent measurements of IL-8 (Assay Designs/Enzo Life Sciences; Farmingdale, NY, 
USA) and GRO-α (R&D Systems). 
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Angiogenesis assay  
An endothelial tube formation assay was used to measure angiogenesis as previously 
described [15, 16]. HEECs (5x104) were seeded into 24-well tissue culture plates over 
undiluted reduced growth factor Matrigel (BD-Biosciences; San Jose, CA) with or 
without aPL (60µg/ml) or control IgG (60µg/ml). In separate experiments, HEECs were 
plated with NT, LMWH (10µg/ml), ASA (10µg/ml) or both LMWH and ASA (each at 
10µg/ml) in the presence of either media or aPL (60µg/ml). Following an 8hr incubation, 
the formation of vessel tube-like structures was monitored by light microscopy (Carl-
Zeiss Observer Z1). Four fields per well were recorded using OpenLab software (Perkin 
Elmer). The number of tubes per field were counted manually by two individuals, 
independently, and the two sets of data for each field were averaged. 
 
Statistical analysis 
Each experiment was performed at least three times. All analyses were performed at least 
in duplicate. All data are reported as mean ± standard error of the mean (SEM) of pooled 
experiments. Statistical significance was set at p<0.05 and determined using Prism 
Software (Graphpad, Inc; La Jolla, CA). For normally distributed data, significance was 
determined using either one-way analysis of variance (ANOVA) for multiple 
comparisons or a t-test. For data not normally distributed, significance was determined 
using a non-parametric multiple comparison test for multiple comparisons or the 
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Domain V aPL, IIC5, alter HEEC angiogenic factor and chemokine secretion  
 
Figure 1. Effect of aPL on HEEC angiogenic factor and chemokine secretion. HEECs 
were treated with no treatment (NT), aPL (IIC5), or control IgG. Data are pooled from 9 
independent experiments. Bar charts show secreted levels of VEGF; PlGF; sFlt-1; 
sEndoglin; MCP-1; G-CSF; GRO-α; IL-8; and GM-CSF as determined by ELISA and 
multiplex analysis. *p<0.05 relative to the NT control. 
 
The first objective of this study was to measure the effects of the anti-β2GPI aPL, IIC5, 
that recognizes domain V of β2GPI on the HEEC angiogenic and cytokine/chemokine 
factor profile. Compared to the no treatment (NT) control, aPL significantly increased 
HEEC secretion of: pro-angiogenic VEGF by 20.5±8.7-fold; pro-angiogenic PlGF by 
3.7±0.8-fold; and anti-angiogenic sFlt-1 by 2.4±0.4-fold (Figure 1). The IgG control had 
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no significant effect on HEEC secretion of VEGF, PlGF, or sFlt-1 (Figure 1). Neither 
aPL, nor the IgG control had any significant effect on HEEC production of sEndoglin 
compared tp the NT control (Figure 1). Treatment of HEECs with aPL significantly 
reduced basal MCP-1 secretion by 44.8±7.3%; G-CSF by 31.0±12.8%; and GRO-α by 
37.5±4.6% when compared to the NT control. The IgG control had no significant effect 
on HEEC secretion of MCP-1, G-CSF, or GRO-α (Figure 1). Neither aPL, nor the IgG 
control, had any significant effect on HEEC production of IL-8 or GM-CSF compared to 
the NT control (Figure 1), and all other factors tested by multiplex were below the assay's 
















Domain V aPL, ID2, and Domain I aPL, PI-117, do not alter HEEC angiogenic factor 
and chemokine secretion 
 
Figure 2. Effect of Domain V Abs, ID2, and Domain I Ab, PI-117 on HEEC angiogenic 
factor and chemokine secretion. HEECs were treated with no treatment (NT), ID2, PI-
117 or control IgG. Data are pooled from 9 independent experiments. Bar charts show 
secreted levels of sFlt-1; PlGF; VEGF; MCP-1; G-CSF; GRO-α; sEndoglin; IL-8; and 
GM-CSF as determined by ELISA and multiplex analysis. *p<0.05 relative to the NT 
control. 
 
The next objective was to determine whether the domain I aPL, PI-117, or domain V 
aPL, ID2, also influenced HEEC angiogenic and cytokine/chemokine factor profile. 
Compared to the no treatment (NT) control, ID2, PI-117, and IgG control had no 
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significant effect on HEEC secretion of sFlt-1, PlGF, VEGF, MCP-1, G-CSF, GROα, 
sEndoglin, GM-CSF, or IL-8 (Figure 2). 
 




Figure 3. Effect of IIC5 aPL on HUVEC angiogenic factor and chemokine secretion. 
HEECs were treated with no treatment (NT), aPL, or control IgG. Data are pooled from 3 
independent experiments. Barcharts show secreted levels of VEGF; PlGF; sFlt-1; 
sEndoglin; MCP-1; G-CSF; GRO-α; IL-8; and GM-CSF as determined by ELISA. 




Since HUVECs are commonly used as a model for the study of the endothelium in APS, 
(27-30), we sought to determine if their response to aPL recognizing β2GPI was similar to 
the HEECs. Similar to the HEECs, aPL significantly increased HUVEC secretion of pro-
angiogenic VEGF by 80.4±11.6-fold; pro-angiogenic PlGF by 12.1±0.3-fold; and anti-
angiogenic sFlt-1 by 2.0±0.0-fold when compared to the NT control (Figure 3). The IgG 
control had no significant effect on HUVEC secretion of VEGF, PlGF or sFlt-1 (Figure 
3). In contrast to the HEECs, aPL significantly increased HUVEC secretion of the anti-
angiogenic sEndoglin by 1.6±0.2-fold compared to the NT control, while the IgG control 
had no effect (Figure 3). The aPL-modulated chemokine profile was also distinct. 
Compared to the NT control, aPL significantly increased HUVEC secretion of G-CSF by 
1.8±0.2-fold and significantly reduced GM-CSF secretion by 28.0 ±20.4%, while the IgG 
control had no significant effect (Figure 3). Neither aPL, nor the IgG control, had any 
significant effect on HUVEC production of MCP-1, GRO-α or IL-8 compared to the NT 












Domain V aPL, ID2, and Domain I aPL, PI-117, do not induce a distinct angiogenic 
factor and chemokine profile in HUVECs 
 
Figure 4. Effect of Domain V Ab, ID2, and Domain I Ab, PI-117 on HUVEC angiogenic 
factor and chemokine secretion. HEECs were treated with no treatment (NT), ID2, PI-
117 or control IgG. Data are pooled from 9 independent experiments. Bar charts show 
secreted levels of sFlt-1; PlGF; VEGF; MCP-1; G-CSF; GRO-α; sEndoglin; IL-8; and 
GM-CSF as determined by ELISA and multiplex analysis. *p<0.05 relative to the NT 
control. 
 
Again, since HUVECs are commonly used as a model for the study of the endothelium in 
APS, we sought to determine if their response to ID2 and PI-117 Abs recognizing domain 
V and domain I β2GPI epitopes, respectively, were similar to the HEECs. Compared to 
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the no treatment (NT) control, ID2, PI-117, and IgG control had no significant effect on 
HEEC secretion of sFlt-1, PlGF, VEGF, MCP-1, G-CSF, GRO-, sEndoglin, GM-CSF, or 
IL-8 (Figure 4). 
 
aPL inhibition of  HEEC MCP-1 secretion is mediated by TLR4 
 
 
Figure 5. Effect of TLR4 inhibition on aPL-induced HEEC angiogenic factor and 
chemokine secretion. HEECs were treated with no treatment (NT) or aPL (IIC5) in the 
presence of media or LPS-RS. Supernatants were measured by ELISA for: VEGF; PlGF; 
sFlt-1; MCP-1; G-CSF; and GRO-α. Data are pooled from 3 independent experiments. 





Having established the HEEC angiogenic and chemokine profile induced by the domain 
V aPL, IIC5, the next objective was to investigate the mechanism involved by blocking 
TLR4 function using the antagonist, LPS-RS. aPL-induced secretion of VEGF, PlGF and 
sFlt-1 was not reversed by the presence of LPS-RS, although aPL-induced PlGF was 
slightly yet significantly increased by 1.1±0.1-fold (Figure 5). While LPS-RS 
significantly increased basal MCP-1 levels by 1.3±0.0-fold, in the presence of aPL, MCP-
1 levels were significantly increased by 2.4±0.1-fold, bringing levels back to baseline. 
Thus, the presence of LPS-RS, completely reversed the inhibition of HEEC MCP-1 
secretion induced by aPL (Figure 5). Although LPS-RS slightly, yet significantly, 
increased basal G-CSF levels by 1.2±0.0-fold, there was no significant effect on the 














Effect of LMWH and ASA on HEEC angiogenic factor and chemokine secretion in the 
presence and absence of aPL 
 
Figure 6. Effect of ASA and LMWH on HEEC aPL-induced HEEC angiogenic factor and 
chemokine secretion. HEECs were treated no treatment (NT), ASA, LMWH or both 
(LMWH + ASA) in the presence of media or aPL. Supernatants were measured by 
ELISA for: VEGF; PlGF; sFlt-1; MCP-1; G-CSF; and GRO-α. Data are pooled from 3 
independent experiments. *p<0.05 relative to the NT/media control unless otherwise 
indicated. 
 
Since our understanding of the actions of LMWH and ASA in obstetric APS are 
incomplete, the effects of these therapies, alone and in combination, on HEEC function in 
the presence and absence of aPL were investigated. The findings are summarized in 
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Table 1. As already determined, treatment of HEECs with the domain V aPL, IIC5, 
significantly increased VEGF, PlGF, and sFlt-1; and significantly inhibited MCP-1, G-
CSF and GRO-α secretion compared to the NT/media control (Figure 6).  
 
LMWH and ASA, either alone or in combination, had no effect on basal VEGF secretion. 
When compared to the NT/media control ASA alone significantly reduced basal PlGF by 
19.8±3.8% and G-CSF by 16.4±4.3%. Compared to the NT/media control, LMWH  
alone, or in combination with ASA, significantly increased basal levels of HEEC sFlt-1 
by 2.3±0.1-fold and 2.1±0.1-fold, respectively; increased basal levels of G-CSF by 
1.3±0.1-fold and 1.2±0.1-fold, respectively; and decreased basal levels of MCP-1 by 
31.3±5.0% and 31.3±6.5%, respectively. Compared to the NT/media control, LMWH  
alone significantly decreased basal levels of HEEC GRO-α secretion by 9.7±3.1% 
(Figure 6 & Table 1). Ethanol alone was run as a control for ASA and had no effect on 
any of the factors tested (data not shown), with the exception of GRO-α which was 
significantly inhibited by 25.9±8.1%. Thus, ASA, either alone or in combination with 
LMWH, was excluded from the GRO-α analysis. 
 
LMWH alone significantly reduced the aPL-induced upregulation of HEEC VEGF 
secretion by 24.6±13.5%. However ASA, either alone or in combination, had no effect on 
VEGF production in the presence of aPL. LMWH in combination with ASA significantly 
augmented the aPL-induced upregulation of HEEC PlGF by 1.1±0.0-fold. However 
LMWH alone or ASA alone had no effect on PlGF production in the presence of aPL. 
LMWH either alone, or in combination with ASA, significantly augmented the aPL-
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induced upregulation of HEEC sFlt-1 by 1.4±0.1-fold and 1.6s±0.1-fold, respectively, 
while ASA alone had no effect. LMWH and ASA, either alone or in combination, had no 
effect on the ability of aPL to reduce HEEC MCP-1 secretion. ASA either alone, or in 
combination with LMWH significantly and further reduced the aPL-mediated inhibition 
of HEEC G-CSF by 25.6±4.8% and 17.4±8.9%, respectively, while LMWH alone had no 
effect. LMWH alone further reduced the aPL-mediated inhibition of HEEC GRO-α 




Table 1: Summary of the effects of ASA and LMWH on HEEC angiogenic factor and 











aPL inhibit HEEC angiogenesis  
 
 
Figure 7. Effect of aPL on HEEC tube formation. HEECs were seeded on Matrigel-
coated plates and treated with no treatment (NT), the domain V aPL, IIC5, or control IgG 
control. After 8hrs, tube-like vessels were imaged and quantitative analysis performed. 
Images are from one representative field of one representative experiment (magnification 
10X). Bar chart shows the number of tubes counted per field and pooled from 5 
independent experiments. *p<0.05 relative to the NT control. 
 
The next objective was to determine whether aPL affected vascular development. For 
this, an angiogenesis assay was utilized in which the formation of HEEC vessel tube-like 
structures in Matrigel was measured. When compared to the NT control, the domain V 
aPL, IIC5, significantly reduced the number of HEEC tubes formed by 19.1±9.9%, while 








Effect of LMWH and ASA on HEEC angiogenesis in the presence and absence of aPL 
 
Figure 8. Effect of ASA and LMWH on HEEC tube formation in the presence and 
absence of aPL. HEECs were seeded on Matrigel-coated plates and treated with no 
treatment (NT), ASA, LMWH or both (LMWH + ASA) in the presence of media or the 
domain V aPL, IIC5. After 8hrs, tube-like vessels were imaged and quantified. Images 
are from one representative field of one representative experiment (magnification 10X). 
Bar chart shows the number of tubes counted per field and pooled from 4 independent 
experiments. *p<0.05 relative to the NT/media control unless otherwise indicated. 
 
When compared to the NT/media control, HEEC tube formation was significantly 
reduced by 27.9±15.1% in the presence of ASA alone, by 30.2±14.2% in the presence of 
LMWH alone, and by 24.1±14.5% in the presence of combination LMWH and ASA 
(Figure 8). The ethanol control had no effect on the basal HEEC tube formation (Data not 
shown). As already determined, treatment of HEECs with aPL significantly inhibited 
HEEC tube formation by 26.3±9.1% compared to the NT/media control. LMWH and 
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ASA, either alone or in combination, had no additional effect on the numbers of HEEC 
tubes formed in the presence of aPL (Figure 8). 
 
DISCUSSION 
Obstetric APS, once thought of as a thrombotic disease, is now known to be 
inflammatory in origin and associated with placental insufficiency and reduced vascular 
development and remodeling [6]. One major way in which aPL negatively impact 
pregnancy is by targeting the placenta, via alteration of trophoblast function [107-109]. 
During pregnancy, aPL recognizing β2GPI can also affect the maternal side of the 
interface by binding directly to the uterine endothelium [4, 15-17] which provides the 
scaffolding upon which trophoblast cells transform the maternal spiral arteries [10]. 
However, little is known about how aPL influence the function of these human 
endometrial endothelial cells (HEECs). Furthermore, little is known about the impact the 
current therapeutics for obstetric APS have on HEEC function. Herein, we report that an 
aPL recognizing domain V of β2GPI modulates HEEC angiogenic factor and chemokine 
production, in part through TLR4 activation, and disrupts angiogenesis. Furthermore, 
LMWH and ASA, in general, exacerbate rather than protect against these aPL-mediated 
changes in HEEC function.  
Previous studies found that aPL inhibits HEEC VEGF secretion; STAT3 
phosphorylation; NFκB activity; and their ability to form vessel tube-like structures in 
vitro [107-109]. However, little else was known about their responses to aPL or the 
mechanisms involved. What these studies did highlight was a role for domain V of β2GPI 
as the peptide TIFI, that shares homology with the aPL-binding site of domain V, blocked 
41	
	
these responses [17]. In our current study, using an aPL that binds to domain V of β2GPI, 
[101] we found that HEEC pro-angiogenic (VEGF, PlGF) and anti-angiogenic factor 
production (sFlt-1) was augmented, while basal chemokine secretion (MCP-1, G-CSF, 
GRO-α) was inhibited. In addition, HEEC angiogenesis was inhibited. While anti-
angiogenic sFlt-1 is associated with promoting hypertension and proteinuria in 
preeclampsia [110] there is also evidence that sFlt-1 contributes to poor placentation by 
impairing endothelial function, impacting uterine vessel remodeling [111, 112] and 
blocking the action of VEGF and PlGF, which promote trophoblast differentiation and 
invasion [113] and angiogenesis [114-116]. Thus, although HEEC production of pro-
angiogenic VEGF and PIGF was also increased, the elevated sFlt-1 response may 
contribute to the impaired HEEC angiogenesis that we, and others [15-17], have 
observed. Moreover, the aPL-induced upregulation of HEEC VEGF production may 
drive the sFlt-1 response [116]. The differences in our studies demonstrating elevated 
HEEC VEGF secretion in response to aPL, while Di Simone’s group showed a reduction 
in this pro-angiogenic factor, may be explained by differences in culture conditions or in 
the use of our monoclonal domain V aPL compared to their use of polyclonal aPL [15, 
16].  
In this study, we also found that aPL suppressed HEEC secretion of chemokines 
that promote trophoblast invasion (G-CSF) [117], and recruit macrophages and natural 
killer cells (MCP-1, GRO-α) that are necessary for normal spiral artery remodeling [50, 
51, 118, 119]. These data suggest that aPL may contribute to the shallow trophoblast 
invasion and disrupted spiral artery transformation seen in obstetric APS by directly 
impacting the uterine endothelium, in addition to targeting the placental trophoblast [41, 
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120]. Furthermore, we observed that under basal conditions, in general, HEECs produced 
higher levels of chemokines compared to the angiogenic factors. This may reflect the 
normal function of uterine endothelial cells in playing an important role in immune cell 
recruitment at the maternal-fetal interface for successful vascular remodeling [121]. Our 
studies also highlight that being of fetal origin, and generating a distinct angiogenic and 
chemokine profile in response to aPL, HUVECs may not be the best model for studying 
the endothelium in either systemic or obstetric APS.  
A role for TLR4 has been demonstrated in aPL-mediated thrombosis [58, 61] and 
in aPL-mediated trophoblast inflammation [65]. In studies using HUVECs, β2GPI 
interacts directly with TLR4 and mediates aPL-induced endothelial cell activation [55, 
72, 73, 122]. HEECs express functional TLRs, including TLR4 [97]. In this current 
study, TLR4 was found to mediate the aPL-induced suppression of HEEC MCP-1 
secretion, but was not involved in any of the other responses tested, suggesting a role for 
additional cell surface receptors that aPL may recruit. These could include TLR2 [59] or 
ApoER2 [123].  
Finally, our studies confronted the debate amongst domain specificity and aPL 
pathogenicity. Domain V ID2 and IIC5 have previously been shown to mediate changes 
in trophoblast secretion [92] and PI-117 has demonstrated lupus anticoagulant activity 
[104]. However, the reaction of HEECs and HUVECs, both endothelial cells, show that 
specific epitopes, even more specific than the general domain to which aPL bind, indicate 
what types of aPL are more deleterious to endothelial cells.  
LMWH is commonly used as an anticoagulant treatment in systemic APS, and 
early initiation of aspirin (prior to 16 weeks of gestation) is thought to be beneficial for 
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fetal development [124]. Both therapies are given empirically to women with recurrent 
miscarriage, whether it is due to APS or not [75, 125, 126]. In women with aPL, while 
LMWH, either alone or in combination with aspirin, has been shown to decrease rates of 
fetal loss, results are conflicting [83, 89, 91, 127, 128]. Furthermore, despite treatment, 
women with APS continue to have high rates of late gestational complications [84, 125, 
129, 130]. Given these controversies, we sought to elucidate the action of LMWH and 
ASA either alone or in combination on HEEC function in the absence and presence of 
aPL. 
In the absence of aPL, LMWH and ASA, alone and in combination, induced 
potentially detrimental angiogenic and chemokine effects on HEECs, somewhat akin to 
aPL treatment. Similar to what has been found in the trophoblast [88, 105, 107, 131]. 
LMWH induced the release of sFlt-1, confirming this observation in endothelial cells 
from other sources [132]. LMWH also reduced HEEC angiogenesis, potentially as a 
consequence of the overwhelming sFlt-1 release [111, 112], which again has been 
observed in other endothelial cell types [132]. Interestingly, ASA had a similar effect by 
inhibiting HEEC tube formation, an observation also seen in HUVECs [114, 115]. As a 
result, combination of LMWH and ASA increased HEEC sFlt-1 release and limited 
angiogenesis. Both single and combination therapies also reduced basal HEEC 
chemokine production. 
 This may be because LMWH can act through non-thrombotic pathways, by 
inhibiting inflammation [65, 85, 105] and ASA is an anti-inflammatory agent [133, 134]. 
In the context of aPL, LMWH alone further augmented aPL-induced HEEC sFlt-1 
release, further reduced GRO-α secretion, and reduced aPL-induced VEGF, while ASA 
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alone further reduced HEEC G-CSF secretion. In combination, LMWH and ASA further 
augmented aPL-induced HEEC sFlt-1 and PlGF release, and further reduced G-CSF 
secretion. Thus, the net effect of LMWH and ASA was the exacerbation of aPL-induced 
changes in the HEEC angiogenic factor and chemokine profile. Additionally, there was 
no reversal of the aPL inhibition of HEEC angiogenesis by either single or combination 
therapy. 
In summary, HEECs produce a number of chemokines and pro-angiogenic factors 
that may promote trophoblast invasion, immune cell recruitment, and spiral artery 
remodeling, to establish the adequate placentation and vascular development needed for a 
healthy pregnancy. An aPL recognizing domain V of β2GPI dysregulates this HEEC 
angiogenic factor and chemokine profile, and limit angiogenesis. Thus, the uterine 
endothelium may contribute to impaired placentation and vascular transformation seen in 
women with obstetric APS. LMWH and ASA, either alone or in combination, may 
further contribute to endothelial dysfunction in the setting of aPL, which may explain the 
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